Baseline perceived stress as a predictor of ketamine/esketamine treatment response in treatment-resistant depression
Journal of Affective Disorders · 2025
DOI: 10.1016/j.jad.2025.04.117 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Affective Disorders, 2025. Verfasst von Stefanie Cavalcanti und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States of America. Hauptthemen laut MEDLINE: Ketamine, Depressive Disorder, Treatment-Resistant, Stress, Psychological, Antidepressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, National Institutes of Health, National Center for Advancing Translational Sciences.
Themen: Depression
Abstract (Originalsprache)
BACKGROUND: Chronic stress is a risk factor for depression and may contribute to treatment resistance. This historical cohort study examined the association between baseline perceived stress, measured with the Perceived Stress Scale (PSS), and response to (es) ketamine in treatment-resistant depression (TRD). METHOD: Adult TRD patients who received intravenous racemic ketamine or intranasal esketamine were included. Depression symptoms were evaluated using the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR). Baseline stress was assessed using the PSS, with scores categorized into low to moderate (PSS < 27) and high (PSS ≥ 27) stress. Statistical tests, including Pearson correlation, Fisher's exact test, and Kruskal-Wallis tests, were used to explore associations between baseline stress, remission (QIDS-SR ≤ 5), and the number of treatments required for remission. Firth's logistic regression model estimated odds ratios (ORs) and 95 % confidence interval (CI). RESULTS: Among 39 patients (median age 47, 61.5 % female), 66.7 % had high perceived stress. Patients with high PSS scores required more treatments for remission (median = 3 vs. 1, p = 0.04). Each 5-point PSS increase reduced remission odds by 60 % (OR = 0.40, 95 % CI: 0.14-0.81, p = 0.009), adjusting for stimulant use. Notably, these effects were independent of baseline depression severity. LIMITATIONS: The study's observational design and lack of a placebo group limit the findings. CONCLUSIONS: TRD patients with high baseline perceived stress had lower odds of remission, and required more treatments to achieve remission. Further research should investigate whether stress-reduction strategies combined with ketamine could enhance treatment outcomes and whether responses differ between acute and chronic perceived stress.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States of America.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States of America.
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States of America. Electronic address: singh.balwinder@mayo.edu.
Förderung
- NCATS NIH HHS
- National Institutes of Health
- National Center for Advancing Translational Sciences
Zitieren
APA
Cavalcanti, S., Pazdernik, V. K., Vande Voort, J. L., Kung, S., & Singh, B. (2025). Baseline perceived stress as a predictor of ketamine/esketamine treatment response in treatment-resistant depression. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.04.117
Vancouver
Cavalcanti S, Pazdernik VK, Vande Voort JL, Kung S, Singh B. Baseline perceived stress as a predictor of ketamine/esketamine treatment response in treatment-resistant depression. Journal of Affective Disorders. 2025. doi:10.1016/j.jad.2025.04.117
BibTeX
@article{Cavalcanti2025,
author = {Cavalcanti, Stefanie and Pazdernik, Vanessa K and Vande Voort, Jennifer L and Kung, Simon and Singh, Balwinder},
title = {Baseline perceived stress as a predictor of ketamine/esketamine treatment response in treatment-resistant depression},
journal = {Journal of Affective Disorders},
year = {2025},
doi = {10.1016/j.jad.2025.04.117}
}
EUVIMED